Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 17/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203945 | 0.85 | TAAR1 (0.49) | TAAR1ADRA2ABACE1KCNH2BACE2 | |
| SCHEMBL7924445 | 0.83 | TAAR1 (0.54) | TAAR1ADRA2ABACE1KCNH2CTSD | |
| SCHEMBL7917980 | 0.83 | TAAR1 (0.54) | TAAR1ADRA2ABACE1KCNH2CTSD | |
| SCHEMBL7917914 | 0.83 | TAAR1 (0.54) | TAAR1ADRA2ABACE1KCNH2CTSD | |
| SCHEMBL7917983 | 0.82 | TAAR1 (0.47) | TAAR1ADRA2ABACE1KCNH2CTSD | |
| SCHEMBL12203946 | 0.82 | TAAR1 (0.47) | TAAR1ADRA2ABACE1CTSD | |
| SCHEMBL7918292 | 0.81 | ADRA2A (0.52) | TAAR1ADRA2ABACE1BACE2CTSD | |
| SCHEMBL7925689 | 0.81 | ADRA2A (0.52) | TAAR1ADRA2ABACE1BACE2CTSD | |
| SCHEMBL7923456 | 0.81 | TAAR1 (0.57) | TAAR1ADRA2ABACE1CTSBCTSD | |
| SCHEMBL7924157 | 0.80 | TAAR1 (0.57) | TAAR1ADRA2ABACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2010042473-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | TAAR1 162/4885ADRA2A 3/4885BACE1 2516/4885 |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRB3 | TAAR1 145/4885ADRA2A 4/4885BACE1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.